J&J Cancer Drug Erleada Cuts Risk of Spread and Death
A late-stage trial showed that adding Erleada to hormone therapy before and after surgery significantly improved outcomes for high-risk prostate cancer patients. The regimen reduced the risk of cancer recurrence or death by up to 29% and nearly doubled the time before patients required subsequent treatment.
Johnson & Johnson reported that its drug Erleada reduced the risk of cancer spread or death by 20% when used before and after surgery. The late-stage study followed patients with high-risk localized prostate cancer for over five years. The data suggests a shift in the standard of care for about 40% of the 330,000 people diagnosed with prostate cancer annually in the United States.
### Erleada Outperforms Standard Hormone Therapy Patients receiving Erleada with hormone-blocking therapy were nine times more likely to have little to no detectable cancer at the time of surgery. The regimen reduced the risk of disease progression or death by 20% compared to those receiving testosterone-blocking therapy alone. Johnson & Johnson presented these findings at the American Society of Clinical Oncology meeting in Chicago on Sunday.
